Talk:Immunoglobulin therapy: Difference between revisions
Jump to navigation
Jump to search
imported>Fire Created page with "{{Infobox drug | drug_name = | INN = | type = <!-- empty --> | image = | width = | alt = | caption = <!-- Clinical data --> | pronounce = | tradename = Flebogamma, Gammagard, Hizentra, others | Drugs.com = {{Drugs.com|monograph|immune-globulin}} | MedlinePlus = | licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->..." |
(No difference)
|
Latest revision as of 17:04, 3 January 2023
| Clinical data | |
|---|---|
| Trade names | Flebogamma, Gammagard, Hizentra, others |
| Other names | normal human immunoglobulin (HNIG), human normal immunoglobulin (HNIG) |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous, intramuscular, subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
- ↑ 1.0 1.1 "Xembify APMDS". Therapeutic Goods Administration (TGA). 15 July 2022. Archived from the original on 14 July 2022. Retrieved 17 July 2022.
- ↑ "Regulatory Decision Summary - Xembify". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
- ↑ "Summary Basis of Decision - HyQvia". Health Canada. 23 October 2014. Retrieved 6 August 2022.